Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lacombe

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|July 2, 1999
Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of CancerJ Vinholes, R Coleman, D Lacombe, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development groupE Briasoulis, N Pavlidis, C Terret, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancersC Theodore, L Geoffrois, J B Vermorken, et al.
Scientific Reports|March 4, 2018
Metabolic Reprogramming in Amyotrophic Lateral SclerosisM Szelechowski, N Amoedo, E Obre, et al.
AMB : Revista Da Associacao Medica Brasileira|March 1, 1973
[Duodenal stasis and pancreatitis. Experimental study]O M Vieira, C A de Andrade, H Murad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
American Journal of Medical Genetics. Part A|June 29, 2010
Rubinstein-Taybi syndrome and Hirschsprung disease in a patient harboring an intragenic deletion of the CREBBP geneB Isidor, G Podevin, C Camby, et al.
European Journal of Cancer (Oxford, England : 1990)|July 4, 2006
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursM J A de Jonge, H Dumez, J Verweij, et al.
Journal of Medical Genetics|March 11, 2000
Tandem duplication within the neurofibromatosis type 1 gene (NF1) and reciprocal t(15;16)(q26.3;q12.1) translocation in familial association of NF1 with intestinal neuronal dysplasia type B (IND B)M Bahuau, I Laurendeau, A Pelet, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|July 2, 1999
Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of CancerJ Vinholes, R Coleman, D Lacombe, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development groupE Briasoulis, N Pavlidis, C Terret, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancersC Theodore, L Geoffrois, J B Vermorken, et al.
Scientific Reports|March 4, 2018
Metabolic Reprogramming in Amyotrophic Lateral SclerosisM Szelechowski, N Amoedo, E Obre, et al.
AMB : Revista Da Associacao Medica Brasileira|March 1, 1973
[Duodenal stasis and pancreatitis. Experimental study]O M Vieira, C A de Andrade, H Murad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
American Journal of Medical Genetics. Part A|June 29, 2010
Rubinstein-Taybi syndrome and Hirschsprung disease in a patient harboring an intragenic deletion of the CREBBP geneB Isidor, G Podevin, C Camby, et al.
European Journal of Cancer (Oxford, England : 1990)|July 4, 2006
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursM J A de Jonge, H Dumez, J Verweij, et al.
Journal of Medical Genetics|March 11, 2000
Tandem duplication within the neurofibromatosis type 1 gene (NF1) and reciprocal t(15;16)(q26.3;q12.1) translocation in familial association of NF1 with intestinal neuronal dysplasia type B (IND B)M Bahuau, I Laurendeau, A Pelet, et al.
Pageof 23